Charozetta - instructions for use, reviews, analogs and forms of release (75 μg tablets) of a contraceptive for women, including during pregnancy and lactation. Skipping and side effects of taking medication

In this article, you can read the instructions for using the drug Charozette. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Charozette in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Charozetta in the presence of existing structural analogs. Use as a contraceptive in women, including during pregnancy and lactation.

Charozette is a gestagen-containing oral contraceptive. Contains gestagen desogestrel. Like other gestagen-containing oral contraceptives ("mini-drank"), Charozetta is best suited for use during breastfeeding and for women who are contraindicated or who do not want to take estrogens. In contrast to the "mini-drank", the contraceptive effect of the Charozette preparation is achieved mainly by suppressing ovulation. Other effects include an increase in the viscosity of cervical mucus.

When using Charozetta in the first 56 days, the frequency of ovulation does not exceed 1%, after stopping the 56-day drug, ovulation occurs after 7-30 days (an average of 17 days).

In a comparative study of efficacy (in which it was allowed to take missed tablets for a maximum of 3 hours), the overall Perl index (an indicator reflecting the frequency of pregnancy in 100 women during the year of using the contraceptive) of the Charozetta drug was 0.4 in the group of all patients enrolled.

The Perl index of the Charozetta preparation is comparable to the Perl index of combined oral contraceptives in the general population taking oral contraceptives.The administration of Charozetta leads to a decrease in the serum estradiol level, to the values ​​characteristic of the early follicular phase. At the same time, there were no clinically significant changes in the carbohydrate, lipid metabolism and hemostasis parameters.

Pharmacokinetics

After taking Charozette's medication internally, desogestrel is rapidly absorbed and converted to an active metabolite, ethonogestrel. Etonogestrel is excreted in breast milk. Desogestrel is converted by hydroxylation and dehydrogenation into the active metabolite ethonogestrel. Etonogestrel is metabolized through the formation of sulfate and glucuronide conjugates.

Indications

• contraception.

Forms of release

The tablets covered with a cover of 75 mkg.

Instructions for use and how to use them

The drug should be taken 1 tablet a day, daily, at the same time, for 28 days, in the order indicated on the package. Receipt of each subsequent package should be started immediately after the end of the previous one, without any interruption. The taken tablet can be washed down with a small amount of liquid.

In the absence of a previous intake of hormonal contraceptives (for the last month)

Tablets should be taken on the 1st day of the menstrual cycle (1st day of menstrual bleeding). It is possible to start on the 2nd-5th day, but then during the first cycle during the first 7 days of taking the drug it is recommended to use an additional (barrier) method of contraception.

Transition from a combined hormonal contraceptive (combined oral contraceptive, vaginal ring or transdermal patch)

The woman should start taking the Charozette drug preferably the day after taking the last active tablet of the combined oral contraceptive (last tablet containing the active substance) or on the day of removal of the vaginal ring or patch. In these cases, there is no need for additional contraception.

At the latest, a woman can also start taking Charozette on the day after the usual interval in taking the pills, plaster, ring, or the day after taking the placebo tablets of the previous combined oral contraceptive (ie, the day the new packaging of a combined oral contraceptive,insert a new ring or glue a new patch), but during the first 7 days of taking the tablets, an additional barrier method of contraception is recommended.

Transition from other drugs containing only progestogen ("mini-drank", injections, implants or gestagen-releasing intrauterine system)

A woman who takes "mini-drank" can go to Charozetta's reception any day. A woman using an implant or an intrauterine system is on the day of their removal. A woman who uses injectable contraceptive forms is the day the next injection is to be made. In all these cases, an additional contraceptive method is not required.

After an abortion made in the first trimester, it is recommended to start taking the medication immediately; an additional contraceptive method is not required.

After childbirth or abortion, made in the 2nd trimester

The drug can be taken no earlier than 21-28 days after the abortion, made in the second trimester, and not earlier than 6 weeks after childbirth. At the beginning of taking the drug at a later date, the barrier method of contraception must be additionally applied during the first 7 days of taking the tablets.However, if a woman has had sexual intercourse after giving birth or having an abortion prior to taking Charozetta, before the use of the drug, pregnancy should be excluded or the woman must wait for the first menstruation.

Skipping the next dose of the drug

Contraceptive protection may decrease if the interval between taking two tablets is more than 36 hours. If the delay in taking the tablet is less than 12 hours, the missed tablet should be taken as soon as the woman remembers it and the next pill should be taken at the usual time. If the delay in taking the tablet is more than 12 hours, the woman should follow the above recommendations, and also apply an additional contraceptive method within the next 7 days. If the pills were missed in the very first week of taking the drug and there was a sexual intercourse during the week preceding the missed intake of tablets, pregnancy should be excluded.

Recommendations in case of vomiting

In the case of severe gastrointestinal disorders (vomiting, diarrhea), absorption may be incomplete and in this case additional contraceptive methods should be used.If vomiting occurs within 3-4 hours after ingestion, the absorption may be incomplete. In this case, it is necessary to be guided by the recommendations regarding the intake of missed tablets.

Side effect

• mood change;
• headache;
• increased fatigue;
• nausea, vomiting;
• irregular spotting;
• amenorrhea;
• decreased libido;
• vaginitis;
• dysmenorrhea;
• ovarian cysts;
• tenderness of the mammary glands;
• increase in body weight;
• rash, hives;
• discomfort when using contact lenses.

Contraindications

• established or suspected pregnancy;
• the presence at the time or in an anamnesis of venous thromboembolism (including deep vein thrombosis of the lower leg, thromboembolism of the pulmonary artery);
• presence at the moment or in an anamnesis of severe liver disease (as long as the liver function is not normalized);
• hepatic insufficiency, incl. in the anamnesis;
• established or suspected malignant hormone-dependent tumors;
• bleeding from the vagina of an unclear etiology;
• lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
• hypersensitivity to the active substance or any auxiliary substance of the drug.

Application in pregnancy and lactation

In pregnancy, the use of the drug is contraindicated.

The results of preclinical studies have shown that very high doses of gestagens can cause masculinization of the female fetus.

Extensive epidemiological studies revealed neither an increased risk of birth defects in children whose mothers took oral contraceptives prior to pregnancy, nor a teratogenic effect with unintentional intake of oral contraceptives in the early period of pregnancy. The drug Charosette does not affect the amount or quality (concentrations of proteins, lactose or fats) of breast milk. However, a small amount of etonogestrel is excreted in breast milk. As a result, 0.01-0.05 mkg of etonogestrel per kg of body weight per day can be delivered to the baby's body (based on consumption of 150 ml / kg per day of breast milk).

There is limited data on long-term follow-up of children whose mothers started taking Charozetta during the 4th-8th week after childbirth.The duration of breastfeeding was 7 months, and children were monitored until reaching the age of 1.5 (n = 32) or up to 2.5 years (n = 14). The evaluation of growth, physical and psychomotor development did not reveal any differences with the babies whose mothers used copper intrauterine spirals. The available data say that the preparation Charosette can be used during lactation. Nevertheless, it is necessary to carefully monitor the development and growth of the infant, whose mother uses the drug Charosette.

special instructions

Before the appointment of the drug should carefully collect anamnesis in women and conduct a thorough gynecological examination to exclude pregnancy. Before the appointment of the drug should determine the cause of menstrual irregularities, for example, oligomenorrhoea and amenorrhea. The interval between the control medical examinations is determined by the doctor in each individual case (the frequency of the examinations is at least 1 time per year). If the prescribed drug can affect the latent or existing disease, an appropriate schedule of control medical examinations should be made.

Despite the regular administration of Charozette, occasional spotting can sometimes occur. If bleeding is very frequent and irregular, consider using another method of contraception. If the above symptoms are stable, then in this case it is necessary to exclude organic pathology. Tactics for amenorrhoea during the use of the drug depend on whether the pill was taken according to the instructions, and may include a pregnancy test. In case of pregnancy, the drug should be stopped.

In case of acute or chronic violations of the liver, a woman should consult a specialist for examination and consultation.

STDs and HIV infection

Women should be informed that Charozette does not protect against HIV infection and other sexually transmitted diseases.

Decreased efficiency

The effectiveness of gestagen-containing oral contraceptives can be reduced in case of missing tablets, gastrointestinal disorders or when taking other medications.

Changes in the nature of menstruation

During the use of gestagen-containing contraceptives in some women, vaginal bleeding may become more frequent or more prolonged, while in other women these bleeding may become more rare or even stop. These changes are often the reason that a woman refuses this method of contraception, or ceases to strictly follow the doctor's instructions. With detailed consultation with women who decided to start taking Charozetta, the doctor should discuss the possibility of such changes in the nature of the menstrual cycle. Evaluation of vaginal bleeding should be based on a clinical picture and may include an examination to exclude malignant neoplasms or pregnancy.

Development of follicles

With the intake of all low-dose hormonal contraceptives, follicles develop, and occasionally the size of the follicle can reach sizes larger than those in the normal cycle. In general, these enlarged follicles disappear spontaneously. Often this occurs without symptoms; in some cases there is a slight pain in the lower abdomen. Surgical intervention is rarely required.

Lab tests

Data on combined oral contraceptives have shown that the use of hormonal contraceptives may affect the results of some laboratory tests, including biochemical parameters of liver, thyroid, adrenal and kidney function, on serum transport proteins, for example globulin , binding corticosteroids, lipid / lipoprotein fractions, carbohydrate metabolism and blood coagulation and fibrinolysis. Usually these changes remain within the normal range. It is not known to what extent this also applies to contraceptives containing only gestagen.

Mammary cancer

The risk of breast cancer increases with age. During the use of combined oral contraceptives, the risk that a woman will be diagnosed with breast cancer is slightly increased. This increased risk gradually disappears within 10 years after discontinuation of the use of oral contraceptives, it is not associated with the duration of use, but depends on the age of the woman during the use of combined oral contraceptives.

Venous thromboembolism

Diabetes

Although gestagens can influence the resistance of peripheral tissues to insulin and glucose tolerance, there is no evidence that there is a need to change the therapeutic regimen in diabetics using gestagen containing oral contraceptives. However, women with diabetes should be closely monitored during the first months of use.

Mineral density of bone tissue

The use of Charozetta leads to a decrease in the serum estradiol level to the level corresponding to the early follicular phase. To date, it is not known whether this reduction has any clinically significant effect on bone mineral density.

Prevention of ectopic pregnancy

Prevention of ectopic pregnancy with traditional gestagen-containing oral contraceptives ("mini-pili") is not as effective as in combined oral contraceptives, since "mini-pili" often results in ovulation. Despite the fact that Charozetta effectively suppresses ovulation,In the case of amenorrhea or abdominal pain, ectopic pregnancy should be excluded when conducting differential diagnosis.

Impact on the ability to drive vehicles and manage mechanisms

Based on the pharmacodynamic profile, it is believed that the Charosette preparation does not affect the ability to drive vehicles and work with mechanisms.

Drug Interactions

The interaction between oral contraceptives and other medications can lead to breakthrough bleeding and / or a decrease in contraceptive effectiveness. In the literature, the following interaction is reported (mainly with combined contraceptives, but sometimes also reported for gestagen-containing contraceptives).

There may be interaction with drugs that induce microsomal enzymes, which leads to an increase in the clearance of sex hormones (hydantoins (eg, phenytoin), barbiturates (eg, phenobarbital), primidone, carbamazepine, rifampicin, oxcarbazepine, rifabutin, topiramate, felbamate, ritonavir, nelfinavir , griseofulvin, preparations containing St. John's wort pitted).Women using any of these drugs should temporarily use the barrier method in addition to the drug Charosette or choose another method of contraception. The barrier method of contraception should be used during the application of these drugs and within 28 days after discontinuation of their administration. For women receiving long-term treatment with inducers of hepatic enzymes, the possibility of using a non-hormonal contraceptive method should be considered.

With the use of activated charcoal, the absorption of desogestrel contained in the tablet may decrease and, consequently, contraceptive efficacy may decrease. In this case, follow the recommendations for missed tablets.

Hormonal contraceptives can affect the metabolism of other drugs. Accordingly, drug concentrations in the plasma and in the tissues may both increase (eg, cyclosporin) and decrease.

To identify possible interactions, you should read the instructions for the use of these medicines.

Analogues of the drug Charosette

Structural analogs for the active substance:

• Lactineth.

Similar medicines:

Other medicines: